New Dual-Action antibody enters first human trials for Hard-to-Treat cancers
NCT ID NCT07660432
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called SIM0689 in adults with advanced solid tumors that have stopped responding to standard treatments. SIM0689 is a bispecific antibody designed to block two cancer-promoting pathways (PD1 and VEGF). The trial will first find a safe dose, then expand to see if it shrinks tumors in specific cancer types.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SIM0689 (a bispecific antibody targeting PD1 and VEGF)
- What this could lead to
- If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
- What could go wrong
- This is a very early Phase 1 trial, so the drug may not be safe or effective. Side effects are unknown, and only a small number of participants will receive the optimal dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS MALIGNANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital of Shandong First Medical University
Jinan, Shandong, 250117, China
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450000, China
-
The First Affiliated Hospital, Zhejiang University school of Medicine
Hangzhou, Zhejiang, 310003, China
-
The First Hospital of China Medical University
Shenyang, Liaoning, 110000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.